𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases

✍ Scribed by Francesco Albano; Giorgina Specchia; Luisa Anelli; Antonella Zagaria; Clelia Tiziana Storlazzi; Caterina Buquicchio; Maria Grazia Roberti; Vincenzo Liso; Mariano Rocchi


Book ID
102842994
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
564 KB
Volume
36
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML) and is observed in more than 90% of CML cases. At diagnosis, in 5–10% of CML patients the Ph chromosome is derived from variant translocations other than the standard t(9;22). Deletions adjacent to the translocation junction on the derivative chromosome 9 were recently described by different groups. The deletions may identify a subgroup with a worse prognosis. The presence of similar deletions on the third derivative other than the 9 and 22 chromosomes in CML with variant translocation has never been investigated. We studied three cases of CML variants showing relatively large deletions on the third chromosome involved in the translocation. Known tumor‐suppressor genes (TSGs) or genes involved in signal transduction and in the modulation of cell proliferation were found to be located inside these deleted regions. As an alternative to Knudson's two‐hit model, the β€œhaplo‐insufficiency” hypothesis suggests that the deletion of a single allele of a TSG can play an important role in tumor progression. Our findings suggest that great attention should be paid to the molecular cytogenetic characterization of variant t(9;22) CML patients to unveil fully the biological heterogeneity of CML. Β© 2003 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Heterogenic molecular basis for loss of
✍ Ivan F. Loncarevic; Jennifer RΓΆmer; Heike Starke; Anita Heller; Cordula Bleck; M πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 881 KB

The objective of this study was to characterize the ABL1-BCR fusion gene in 76 BCR-ABL1-positive chronic myeloid leukemia (CML) patients regarding expression as well as genomic status, to assess the frequency of ABL1-BCR gene deletion in these patients, which has been reported to be an adverse progn